ELVN

ENLIVEN THERAPEUTICS, INC.

ELVN · CIK 1672619 · Annual (10-K) · Last 6 years

Financial Trends

Revenue
20202025
Net Income−$104M
20202025
Operating CF−$70M
20202025
Free Cash Flow
20202025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue——————
Cost of Revenue——————
Gross Profit——————
R&D Expense$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
SG&A Expense——————
Operating Income$-0.1B$-0.1B$-0.1B$0.0B$-0.1B$-0.0B
Net Income$-0.1B$-0.1B$-0.1B$0.0B$-0.1B$-0.0B
EPS (Basic)$-1.83$-1.89$-2.01$0.06——
EPS (Diluted)$-1.83$-1.89$-2.01$0.06——

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.5B$0.3B$0.3B$0.1B$0.1B$0.1B
Current Assets$0.5B$0.3B$0.3B$0.1B$0.1B$0.1B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.5B$0.3B$0.2B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.2B$-0.0B$-0.1B$0.1B$-0.0B$-0.0B
Capital Expenditures——————
Financing Cash Flow$0.2B$0.1B$0.2B$-0.0B$0.0B$0.1B
← Companies